Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers.

Boffito M, Jackson A, Lamorde M, Back D, Watson V, Taylor J, Waters L, Asboe D, Gazzard B, Pozniak A.

J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):222-7. doi: 10.1097/QAI.0b013e3181b061d0.

PMID:
19620877
2.

Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers.

Peeters M, Janssen K, Kakuda TN, Schöller-Gyüre M, Lachaert R, Hoetelmans RM, Woodfall B, De Smedt G.

Ann Pharmacother. 2008 Jun;42(6):757-65. doi: 10.1345/aph.1K681. Epub 2008 Apr 29.

PMID:
18445705
3.

Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.

DeJesus E, Lalezari JP, Osiyemi OO, Ruane PJ, Ryan R, Kakuda TN, Witek J.

Antivir Ther. 2010;15(5):711-20. doi: 10.3851/IMP1562.

PMID:
20710052
4.

Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies.

Kakuda TN, Woodfall B, De Marez T, Peeters M, Vandermeulen K, Aharchi F, Hoetelmans RM.

J Antimicrob Chemother. 2014 Mar;69(3):728-34. doi: 10.1093/jac/dkt421. Epub 2013 Oct 23.

PMID:
24155058
5.

Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers.

Kakuda TN, Schöller-Gyüre M, De Smedt G, Beets G, Aharchi F, Peeters MP, Vandermeulen K, Woodfall BJ, Hoetelmans RM.

HIV Med. 2009 Mar;10(3):173-81. doi: 10.1111/j.1468-1293.2008.00668.x. Epub 2009 Jan 7.

6.

A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population.

Nelson M, Stellbrink HJ, Podzamczer D, Banhegyi D, Gazzard B, Hill A, van Delft Y, Vingerhoets J, Stark T, Marks S.

AIDS. 2011 Jan 28;25(3):335-40. doi: 10.1097/QAD.0b013e3283416873.

PMID:
21150563
7.
8.

Pharmacokinetics and pharmacodynamics of etravirine 400 mg once daily in treatment-naïve patients.

Di Perri G, Green B, Morrish G, Hill A, Faetkenheuer G, Bickel M, van Delft Y, Kurowski M, Kakuda T.

HIV Clin Trials. 2013 May-Jun;14(3):92-8. doi: 10.1310/hct1403-92.

PMID:
23835511
9.

Pharmacokinetics of darunavir at 900 milligrams and ritonavir at 100 milligrams once daily when coadministered with efavirenz at 600 milligrams once daily in healthy volunteers.

Soon GH, Shen P, Yong EL, Pham P, Flexner C, Lee L.

Antimicrob Agents Chemother. 2010 Jul;54(7):2775-80. doi: 10.1128/AAC.01564-09. Epub 2010 Apr 12.

10.

Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial.

Kakuda TN, Leopold L, Nijs S, Vandevoorde A, Crauwels HM, Bertelsen KM, Stevens M, Witek J, van Delft Y, Tomaka F, Hoetelmans RM.

J Clin Pharmacol. 2014 May;54(5):563-73. doi: 10.1002/jcph.245.

PMID:
25975423
11.

Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients.

Kakuda TN, Schöller-Gyüre M, Workman C, Arasteh K, Pozniak AL, De Smedt G, Beets G, Peeters M, Vandermeulen K, Woodfall BJ, Hoetelmans RM.

Antivir Ther. 2008;13(5):655-61.

PMID:
18771049
12.

The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers.

Aarnoutse RE, Grintjes KJ, Telgt DS, Stek M Jr, Hugen PW, Reiss P, Koopmans PP, Hekster YA, Burger DM.

Clin Pharmacol Ther. 2002 Jan;71(1):57-67.

PMID:
11823758
13.

Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers.

Sekar VJ, De Pauw M, Mariën K, Peeters M, Lefebvre E, Hoetelmans RM.

Antivir Ther. 2007;12(4):509-14.

PMID:
17668559
14.

Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.

Anderson MS, Kakuda TN, Hanley W, Miller J, Kost JT, Stoltz R, Wenning LA, Stone JA, Hoetelmans RM, Wagner JA, Iwamoto M.

Antimicrob Agents Chemother. 2008 Dec;52(12):4228-32. doi: 10.1128/AAC.00487-08. Epub 2008 Oct 6.

15.

Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.

Schöller-Gyüre M, Kakuda TN, De Smedt G, Woodfall B, Berckmans C, Peeters M, Hoetelmans RM.

Clin Ther. 2010 Feb;32(2):328-37. doi: 10.1016/j.clinthera.2010.02.013.

PMID:
20206790
16.

Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy.

Waters L, Jackson A, Else L, Rockwood N, Newell S, Back D, Nelson M, Gazzard B, Boffito M.

Antivir Ther. 2015;20(2):157-63. doi: 10.3851/IMP2817. Epub 2014 Jun 25.

PMID:
24963558
17.

Intracellular and plasma pharmacokinetics of 400 mg of etravirine once daily versus 200 mg of etravirine twice daily in HIV-infected patients.

Gutiérrez-Valencia A, Martin-Peña R, Torres-Cornejo A, Ruiz-Valderas R, Castillo-Ferrando JR, López-Cortés LF.

J Antimicrob Chemother. 2012 Mar;67(3):681-4. doi: 10.1093/jac/dkr534. Epub 2011 Dec 21.

PMID:
22190606
18.

Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine.

Ramanathan S, Kakuda TN, Mack R, West S, Kearney BP.

Antivir Ther. 2008;13(8):1011-7.

PMID:
19195326
19.

Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects.

Liu P, Foster G, LaBadie RR, Gutierrez MJ, Sharma A.

J Clin Pharmacol. 2008 Jan;48(1):73-84. Epub 2007 Nov 19.

PMID:
18025525
20.

Effects of different meal compositions and fasted state on the oral bioavailability of etravirine.

Schöller-Gyüre M, Boffito M, Pozniak AL, Leemans R, Kakuda TN, Woodfall B, Vyncke V, Peeters M, Vandermeulen K, Hoetelmans RM.

Pharmacotherapy. 2008 Oct;28(10):1215-22. doi: 10.1592/phco.28.10.1215.

PMID:
18823217

Supplemental Content

Support Center